/ Print /

Pharmacy Strategy

Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
Five pharmacy regulations health execs must keep on their radars in 2017Here are five critical regulations that executives can begin to prepare for today.
What more transparency at the FDA means for health executivesResearchers create a set of recommendations for transparency at the agency in five principal areas.
More resources needed for medication-assisted treatmentInclude medication-assisted treatment high on the list of clinical tools used to treat opioid addiction.
ACA reform must preserve mental health pharmacy accessACA repeal or replacement must focus on how to preserve mental health services and pharmacy access.
Cannabinoid-based drug pipeline shows promise
Cannabinoid-based drug pipeline shows promiseNew treatment indications are under investigation for the use of cannabinoid-based drugs.
New strategies for managing drug spend: RA, Cancer, Hep C
New strategies for managing drug spend: RA, Cancer, Hep CThe proliferation of specialty drugs has prompted new techniques for keeping costs in tow.
Cannabinoid-based drug pipeline grows: 4 ways to prepareNew treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready?
Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.